Sagimet Biosciences INC Form 4 insider transactions

Eduardo Bruno Martins, Chief Medical Officer of Sagimet Biosciences Inc., was granted stock options and restricted stock units on February 6, 2025.

David Happel, President & CEO of Sagimet Biosciences, reports acquisition of shares and options in the company.

Elizabeth Rozek, General Counsel and CCO of Sagimet Biosciences Inc., reports the acquisition of stock options and restricted stock units.

Thierry Chauche, CFO of Sagimet Biosciences, reports the acquisition of stock options and restricted stock units.

Jennifer Jarrett, a director at Sagimet Biosciences, acquired stock options on August 1, 2024.

Director Anne M. Phillips acquired stock options in Sagimet Biosciences, vesting monthly over three years.

George Kemble, Executive Chairman of Sagimet Biosciences, sold 23,625 shares of Series A Common Stock at an average price of $3.1674 per share under a pre-arranged Rule 10b5-1 trading plan.

Eduardo Bruno Martins, Chief Medical Officer of Sagimet Biosciences Inc., sold 8,357 shares of Series A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

Elizabeth Rozek, General Counsel and CCO of Sagimet Biosciences Inc., sold shares to cover tax withholding obligations related to vesting restricted stock units.

Executive Chairman of Sagimet Biosciences, George Kemble, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Director Timothy P. Walbert acquired stock options for 9,279 shares of Sagimet Biosciences Inc. on June 5, 2024.

Director Beth C. Seidenberg acquired stock options in Sagimet Biosciences Inc. on June 5, 2024.

Director Merdad Parsey acquired stock options in Sagimet Biosciences Inc. on June 5, 2024.

Director Paul W. Hoelscher acquired stock options in Sagimet Biosciences Inc. on June 5, 2024.

Elizabeth Grammer, a director at Sagimet Biosciences Inc., acquired stock options for 51,459 shares of Series A Common Stock on June 5, 2024.

Thierry Chauche, CFO of Sagimet Biosciences, was granted stock options for 587,181 shares on May 6, 2024, vesting over four years.

Director Timothy P. Walbert of Sagimet Biosciences Inc. acquired stock options on April 1, 2024.

Director Paul W. Hoelscher acquired stock options in Sagimet Biosciences Inc. on April 1, 2024.

David Happel, President & CEO of Sagimet Biosciences Inc., purchased 12,100 shares of Series A Common Stock at an average price of $5.267 on March 26, 2024.